对于急性COPD恶化的急诊室内皮质类固醇处方模式:教育干预后的回顾性分析
Christopher Nedzlek1, Jacob Blanchett1, Zachary Illg1
1Department of Emergency Medicine Henry Ford Wyandotte Hospital, Wyandotte, MI, USA.
Spartan medical research journal
|October 21, 2024
概括
一项教育倡议成功地减少了COPD患者的皮质类固醇处方,降低了甲基普雷迪尼索隆剂量,并减少了住院时间. 这凸显了有针对性的教育对临床实践和患者结果的影响.
科学领域:
- 肺部病理学 肺部病理学
- 临床药房 临床药房
- 医疗保健教育 医疗保健教育
背景情况:
- 慢性阻塞性肺病 (COPD) 是一种流行,进展性肺病,具有显著的空气流限制.
- 管理包括抗生素,支气管扩展剂和皮质类固醇,尽管处方方案各异.
- 皮质类固醇处方的变化需要评估当前的做法和教育干预措施的影响.
研究的目的:
- 评估COPD的基线皮质类固醇处方模式.
- 为了确定一个教育倡议是否可以改变这些处方模式.
- 评估皮质类固醇剂量对停留时间,再接收,死亡率和胰岛素剂量的影响.
主要方法:
- 一个单一机构的回顾性观察研究.
- 提供者填写了关于COPD的皮质类固醇处方的基线问卷.
- 提供了基于证据的建议的教育演讲,随后进行了干预后数据分析.
主要成果:
- 基线:95.3%的提供者使用了125毫克的甲基前尼索隆,通常是由于先前的培训.
- 干预后:甲基普雷迪尼索隆的平均剂量从114.24毫克降至72.8毫克 (p < 0.01).
- 125毫克甲基普雷迪尼索隆使用的显著减少 (69%) 和62.5毫克使用的增加 (42.6%);平均停留时间 (LOS) 从5.80日减少到4.82天 (p = 0.01).
结论:
- 教育干预措施可以有效地改变供应商对COPD的皮质类固醇处方习惯.
- 在急诊室降低皮质类固醇剂量可能会导致患者停留时间缩短.
- 标准化皮质类固醇推可以改善临床实践和患者的治疗结果.
相关概念视频
COPD: Management Using Bronchodilators and Corticosteroids
182
Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
182
Chronic Obstructive Pulmonary Disease-V: Management
2.5K
Managing Chronic Obstructive Pulmonary Disease (COPD) involves a multifaceted approach to reduce symptoms, prevent exacerbations, improve overall health status, and slow disease progression. Key strategies include lifestyle modifications, pharmacotherapy, supportive therapies, and, in some cases, surgery. Here is an overview of the primary COPD management strategies:
Smoking Cessation
Smoking Cessation
2.5K
Chronic Obstructive Pulmonary Disease
1.2K
COPD is defined as a heterogeneous lung condition marked by persistent respiratory symptoms such as dyspnea, cough, and sputum production, caused by abnormalities in the airways that cause airflow obstruction.
Smoking is a primary risk factor for COPD, with over 80% of patients having a history of it. Patients typically experience progressive dyspnea or labored breathing, frequent coughing, and recurrent pulmonary infections. Many eventually succumb to respiratory failure, characterized by...
Smoking is a primary risk factor for COPD, with over 80% of patients having a history of it. Patients typically experience progressive dyspnea or labored breathing, frequent coughing, and recurrent pulmonary infections. Many eventually succumb to respiratory failure, characterized by...
1.2K
Chronic Obstructive Pulmonary Disease-I: Introduction
2.8K
Chronic Obstructive Pulmonary Disease (COPD) is a long-lasting respiratory condition requiring continuous attention and care. It is a progressive lung disease that leads to breathing challenges due to airflow obstruction. It manifests as persistent respiratory symptoms and restricted airflow resulting from abnormalities in the airways and alveoli, usually due to long-term exposure to harmful particles or gases. COPD mainly consists of two primary conditions: emphysema and chronic bronchitis.
2.8K
Drugs Used in Lower Respiratory Disorders: Overview
353
Lower respiratory tract disorders present challenges that often require skilled and nuanced approaches for effective management. Common ailments, such as asthma and chronic obstructive pulmonary disease (COPD), have prompted the development of intricate treatment strategies involving bronchodilators and anti-inflammatory drugs, each tailored to ease breathing and revitalize the lungs.
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
353
Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids
223
Inhaled corticosteroids (ICS) are anti-inflammatory drugs used primarily in treating persistent asthma and providing long-term maintenance. They target the bronchial mucosa, the lining of the airways, to control inflammation, a critical factor in asthma progression and exacerbation.
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
223


